What Happened

Elucid secured $55M in Series D funding from investors including IAG Capital Partners and Elevage Medical Technologies. The oversubscribed round brings total funding to $185M for its FDA-cleared Plaque-IQ AI imaging platform.

Who Is Affected

Medical imaging sales teams should prioritize Elucid as a commercial-ready account. The company confirmed plans to expand partnerships with medtech firms and submit BioIntegrated FFR-CT for FDA 510(k) clearance.

Market Impact

• Validates AI's role in cardiovascular diagnostics with FDA-cleared Plaque-IQ and pending FFR-CT tech
• Creates partnership opportunities for medical imaging and AI vendors
• Signals commercial readiness with recent Lesion Inspection Tool launch

What to Watch

Monitor FDA decisions on FFR-CT and partnership announcements with unnamed "publicly traded medtech" strategic investor. Commercial traction post-Series D will indicate account maturity.

Related coverage

• Moleculin Biotech updates Annamycin data, prices stock offering at $0.75
• Saudi Biotech Fund IB Ventures Launches With $50 Million Raise
• Vaxart Updates BARDA Funding Award for COVID-19 Oral Pill Vaccine Trial
• AI Streamlines Statistical Programming in Clinical Trials, Weikeli Pharmaceutical Seeks Financing